Iguratimod is a small-molecule, disease-modifying antirheumatic drug (DMARD) used in the treatment of rheumatoid arthritis, often in combination with methotrexate. As an immunomodulatory agent, it functions… Read more


















































Iguratimod is a small-molecule, disease-modifying antirheumatic drug (DMARD) used in the treatment of rheumatoid arthritis, often in combination with methotrexate. As an immunomodulatory agent, it functions by inhibiting the production of pro-inflammatory cytokines and modulating B and T lymphocyte activity. The Iguratimod category provides a comprehensive range of high-quality reference standards, including the active pharmaceutical ingredient, process-related impurities, and degradation products. These materials are essential for pharmaceutical laboratories conducting impurity profiling, method development, and validation of analytical procedures such as HPLC and LC-MS. By utilizing these characterized reference materials, researchers can ensure accurate quantitative analysis and monitor the stability of the drug under various stress conditions. Stable isotope labelled compounds within this collection further support precise analytical performance, enabling rigorous quality control to meet regulatory standards throughout the drug development and manufacturing lifecycle.